Follicum receives approval of patent in Korea

Follicum AB (”Follicum”) today announces that the Korean patent office (”KIPO”) has approved the company’s patent application for stimulation of hair growth.

With the approval in Korea, patent number 10-1992282, Follicum has a patent protection in Korean up to and including year 2032. The patent protects the company’s peptides in general and for stimulation of hair growth in particular.

CEO Jan Alenfall comments
- This patent approval is exciting as Korea is an important market for hair growth products. Other than the formal approval from Korea this patent has been approved in the US, Europe, China, Australia, Russia, Hong Kong and Japan. We now have a very good protection regarding our candidate molecule FOL-005 and other peptides on significant markets around the world.

For further information, please contact:
Jan Alenfall – CEO, Follicum AB

Telephone: +46 46 19 21 97
Email: info@follicum.com

This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on July 11th, 2019

About Follicum AB
Follicum is a biotech company focusing on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com.  

Tags:

About Us

Follicum AB (publ) develops drug candidates based on tissue reparing peptides with potential use in several therapeutic areas. The company’s primary candidate, FOL-005 for stimulating hair growth, is currently being evaluated in a phase IIa study in collaboration with internationally reputable specialist clinics. The company’s project in diabetes aims at protecting insulin producing cells against damage and thereby reducing the risk of complications. Based on promising preclinical results preparations for entering a phase I study is ongoing, which expects to be initiated in 2021. Both projects have the potential of becoming so called first-in-class drugs. For more information, please visit www.follicum.com.

Subscribe

Documents & Links